High Court Halts Generic Gilenya As Novartis Appeals IP Loss
The U.S. Supreme Court has blocked for now the mandate of a recent Federal Circuit decision that a Novartis Pharmaceuticals patent covering multibillion-dollar multiple sclerosis drug Gilenya is invalid....To view the full article, register now.
Already a subscriber? Click here to view full article